Goldman Sachs Lowers Estimates on Illumina | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Goldman Sachs today lowered estimates for Illumina following last week's pre-announcement of third-quarter revenues that fall short of Wall Street expectations.

In a research note, analyst Isaac Ro lowered estimates for 2012 through 2014 "as we take a more cautious view on HiSeq placements … consumable pull-through, MiSeq placements, and array growth."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.